According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

The issue with CFTR modulators is that they don’t work on every CF case. However, the company developed its competitive edge ...

The task ahead of Vertex now is to migrate patients already on Trikafta to the new drug. That is supported by data from the ...

Throughout Gunnar Esiason's journey with cystic fibrosis, the sport of hockey has always been huge part of his family. See ...

The FDA's nod is based on late-stage data, which show that treatment with VRTX's Alyftrek enhances patient benefit compared ...

Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...

Alyftrek is approved as a new treatment for cystic fibrosis, while the FDA expanded the label for Trikafta to include additional genetic mutations.

The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion ...

As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $430 from $426 and keeps a Sector Perform rating on the shares.

JPMorgan lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $500 from $503 and keeps an Overweight rating on the shares.

Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.